(S)-b-aminoisobutyric acid是一种经胸腺嘧啶和缬氨酸分解代谢产生的非蛋白质氨基酸。
Cas No.:4249-19-8
Sample solution is provided at 25 µL, 10mM.
(S)-b-aminoisobutyric acid is a non-protein amino acid produced through the catabolism of thymine and valine[1]. (S)-b-aminoisobutyric acid plays a key role in energy metabolism, fatty acid oxidation, and muscle metabolism, and is commonly used in research on cardioprotection, body weight, and energy balance[2,3,4].
In vitro, treatment of H9C2 cardiomyocytes with (S)-b-aminoisobutyric acid (10, 20, 30μM) for 24h concentration-dependently increased the phosphorylation levels of AMP-activated protein kinase (AMPK). (S)-b-aminoisobutyric acid (30μM) treatment of H9C2 cardiomyocytes for 24h significantly restored the reduction in ATP production induced by H2O2[5]. Treatment of bone marrow-derived macrophages (BMMs) with (S)-b-aminoisobutyric acid (60μM) during the early (days 0-2) or middle (days 2-4) stages of osteoclast induction significantly inhibited the formation of TRAP-positive multinucleated cells, whereas treatment during the late stage (days 4-6) showed a weaker inhibitory effect[6].
In vivo, oral administration of (S)-b-aminoisobutyric acid (75 mg/kg/day) by gavage to Sprague-Dawley rats with heart failure (HF) for 8 weeks significantly reduced cardiomyocyte apoptosis (decreased number of TUNEL-positive cells)[5]. Pretreatment of C57BL/6 mice with (S)-b-aminoisobutyric acid (150mg/kg/day) by gavage for 10 days, followed by the establishment of a lung ischemia-reperfusion (I/R) injury model, significantly increased the nuclear translocation of Nrf-2 in the lung tissue of mice with I/R injury[7].
References:
[1] CRUMPLER H R, DENT C E, HARRIS H, et al. β-Aminoisobutyric acid (α-methyl-β-alanine): a new amino-acid obtained from human urine[J]. 1951.
[2] BEGRICHE K, MASSART J, ABBEY‐TOBY A, et al. β‐Aminoisobutyric acid prevents diet‐induced obesity in mice with partial leptin deficiency[J]. Obesity, 2008, 16(9): 2053-2067.
[3] STAUTEMAS J, VAN KUILENBURG A B P, STROOMER L, et al. Acute aerobic exercise leads to increased plasma levels of R-and S-β-aminoisobutyric acid in humans[J]. Frontiers in Physiology, 2019, 10: 1240.
[4] VALLEJO J A, KITASE Y, GANESH T, et al. L-β-aminoisobutyric acid (L-BAIBA) in combination with voluntary wheel running exercise enhances musculoskeletal properties in middle-age male mice[J]. Aging (Albany NY), 2025, 17(10): 2475.
[5] YU Y, CHEN W, YU M, et al. Exercise-generated β-aminoisobutyric acid (BAIBA) reduces cardiomyocyte metabolic stress and apoptosis caused by mitochondrial dysfunction through the miR-208b/AMPK pathway[J]. Frontiers in Cardiovascular Medicine, 2022, 9: 803510.
[6] HUANG Z W, YU Y P, HE X R, et al. Exercise suppresses osteoclastogenesis by increasing the secretion of muscle-derived L-β-aminoisobutyric acid[J]. Journal of Sport and Health Science, 2025: 101077.
[7] ZHANG Z, LI X, GUO J, et al. β-aminoisobutyrics acid, a metabolite of BCAA, activates the AMPK/Nrf-2 pathway to prevent ferroptosis and ameliorates lung ischemia-reperfusion injury[J]. Molecular Medicine, 2023, 29(1): 164.
(S)-b-aminoisobutyric acid是一种经胸腺嘧啶和缬氨酸分解代谢产生的非蛋白质氨基酸[1]。(S)-b-aminoisobutyric acid在能量代谢、脂肪酸氧化和肌肉代谢中起关键作用,通常用于心脏保护、体重和能量平衡的研究[2,3,4]。
在体外,(S)-b-aminoisobutyric acid(10, 20, 30μM)处理H9C2心肌细胞24h,浓度依赖性地增加了AMP激活蛋白激酶(AMPK)的磷酸化水平。(S)-b-aminoisobutyric acid(30μM)处理H9C2心肌细胞24h,显著恢复了由H2O2引起的ATP生成减少[5]。(S)-b-aminoisobutyric acid(60μM)在诱导破骨分化的早期(0-2天)或中期(2-4天)处理骨髓来源巨噬细胞BMMs,可显著抑制TRAP阳性多核细胞的形成,而在晚期(4-6天)处理则抑制作用较弱[6]。
在体内,(S)-b-aminoisobutyric acid(75mg/kg/day)通过口服灌胃处理心力衰竭(HF)的Sprague-Dawley大鼠8周,显著减少了心肌细胞凋亡(TUNEL阳性细胞减少)[5]。(S)-b-aminoisobutyric acid(150mg/kg/day)通过灌胃预处理C57BL/6小鼠10天,后建立肺缺血再灌注(I/R)损伤模型,可显著增加I/R损伤小鼠肺组织中Nrf-2的核内易位[7]。
| Cell experiment [1]: | |
Cell lines | H9C2 cells |
Preparation Method | H9C2 cells were treated with different concentrations of (S)-b-aminoisobutyric acid (10, 20, 30μM) for 24h, and the expression levels of p-AMPK and AMPK were detected by Western Blotting. |
Reaction Conditions | 10, 20, and 30μM; 24h |
Applications | Treatment with (S)-b-aminoisobutyric acid increased the phosphorylation level of AMPK in a concentration-dependent manner. |
| Animal experiment [1]: | |
Animal models | Sprague-Dawley rat with HF |
Preparation Method | Sprague-Dawley rats with HF were treated with (S)-b-aminoisobutyric acid (75mg/kg/day) by oral gavage for 8 weeks, then myocardial apoptosis was assessed using TUNEL staining. |
Dosage form | 75mg/kg/day; 8 weeks; i.g. |
Applications | Treatment with (S)-b-aminoisobutyric acid significantly reduced cardiomyocyte apoptosis (reduction in TUNEL-positive cells). |
References: | |
| Cas No. | 4249-19-8 | SDF | |
| 别名 | L-3-氨基异丁酸 | ||
| Canonical SMILES | O=C(O)[C@@H](C)CN | ||
| 分子式 | C4H9NO2 | 分子量 | 103.12 |
| 溶解度 | Water: 250 mg/mL (2424.36 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
| 1 mM | 9.6974 mL | 48.4872 mL | 96.9744 mL |
| 5 mM | 1.9395 mL | 9.6974 mL | 19.3949 mL |
| 10 mM | 969.7 μL | 4.8487 mL | 9.6974 mL |
| 第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
| 给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
| 第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
















